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Part I: Consumption of Soybean and the incidence of Prostate Cancer in
East and West
Prostate cancer is the most frequently diagnosed malignancy in men all over the world. The
investigation from International Agency for Research on Cancer in World Healthy Organi‐
zation of United Nations reported the data of 899, 000 new cases of prostate cancer in 2008,
accounted for 13.6% of the total cancer cases. The investigation discovered the large differ‐
ence of the incidence and the mortality of prostate cancer between in West and in East (Fig‐
ure 1). In Western countries, the incidences and mortalities are significantly high. For
example, the cases from Australia, Northern America or Europe, occupied nearly three-
quarters of all the globe prostate cancer patients. In contrast, the incidences and mortalities
in Asia are quite low, less than one tenth of that in Europe, the US or Australia of the West,
especially in the South-Central Asia, showing the lowest incidence and mortality [1].
The  significant  difference  of  the  incidences  of  prostate  cancer  addressed several  impor‐
tant questions.
1. Why do Asian men have a much lower incidence of prostate cancer compared to men
from the Western countries (the US and Europe)? Latent or clinically insignificant can‐
cer of the prostate is found at autopsy at approximately the same rate in men from
Asian countries as those from the USA (approximately 30% of men aged over 50 years),
but there are large differences in the clinical incidence and mortality. Is there a strong
possibility that diet and nutrition play a prominent role in accelerating or inhibiting the
process by which clinically significant prostate cancer develops?
2. Is the fact that the hormone-dependent cancers of the prostate and breast show the
same incidence and lifetime risk (the correlation r is 0.81 in 21 countries) related to diet?
© 2013 Li et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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3. East Asian countries, including Chinese and Japanese men, have the lowest incidence of
prostate cancer in the world. But why, when Japanese men from those countries mi‐
grate to the North America, does their risk of developing prostate cancer increase 10-
fold compared to their counterparts in Japan or China?
4. Although it is relatively rare in East, an increase in the incidence of prostate cancer has
been reported in China, where the life style especially the diet structure is changing fol‐
lowed with the developed economy in recent years. What factors can account for the
conspicuous increase?
Figure 1. The incidence and mortality of Prostate cancer in the world, 2008(from International Agency for Research
on Cancer)
Those questions highlight the critical roles of environmental dietary factors in the different
risks of prostate cancer between East and West. Many epidemiological studies suggest that
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the different dietary, most probably one kind of traditional food in the East countries, soy‐
bean, may become a dominant reason for the protective effects against prostate cancer [2].
Soybean, recognized as a complete protein food, is a species of legume and an annual plant
in Asia. As being a traditional food in Asia, the history of soybean in Asia is very long, more
than 5000 years and even before written records. Soybean can be made to a large body of
kinds of foods by fermented or non-fermented process. Typical soy foods include soy milk,
bean curd and tofu skin which are non-fermented soy foods as well as miso sauce, natto and
soy sauce which belong to fermented soy foods. Not only fermented soybean foods, but also
non-fermented soybean products are very essential dietary ingredient for Asian people, es‐
pecially Chinese, Japanese and Koreans. Some Asians often have and their fermented or
non-fermented products almost everyday. Japanese nearly had the soy food daily by inges‐
tion of miso sauce and Chinese approximately had them more than 100 grams per day.
The history of soybean used in western countries is quite short, compared to that in Asia.
Soybean was introduced into America, Australia and New Zealand about in 17th century
and into Canada in 1831 as a sauce named “A new dozen India Soy”. Most westerners hard‐
ly consume soy foods in the diet, although soybean and its products are used largely in
some other ways, for example soybean oil could be made into bio-diesel in the United
States. However  Soy food consumption in the western countries are quite low. Soy foods
have been consumed for centuries in Asian countries Japanese nearly had the soy food daily
by ingestion of miso sauce and Chinese approximately had them by Tofu, soy milk and tofu
skin.. The mean daily intakes of soy protein are approximately 30 grams in Japan, 20 grams
in Korea, 7 grams g in Hong Kong, and 8 grams but more than 100 grams per day in some
area in China [3]. While the average daily intake in the United States is less than 1 gram [4].
Country Prostate
cancer
mortality
Total
energy
Fish energySoy energy Animal
energy
Australia 29.59 3055 22 0 1019
Austria 31.23 3575 15 0 1233
Canada 29.20 3340 29 0 1297
France 31.43 3529 34 0 1343
Italy 22.57 3688 25 0 913
USA 32.19 3641 23 1 1316
Hong Kong 5.44 2771 89 36 834
Japan 5.87 2852 195 93 590
Korea 0.90 3056 67 94 269
Singapore 7.47 3165 63 29 689
Thailand 0.53 2330 37 18 152
Table 1. Prostate cancer and amount of soy food consumption in East and West, 1998 (from JNCI 1998; 90:
1637-1647)
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For clear comparison of soybean in the Asian and the western diet, a table published in JNCI
(Table 1), clearly clarified Prostate cancer and amount of soy food consumption in East and
West. In Asian regions, the soybean energy is 36 in Hong Kong, 29 in Singapore and 18 in
Thailand; and for much more dramatically difference, the soybean energy is 93 in Japanese,
and 94 in Korean diet [5]. In contrast, in western countries of Australia, Austria, Canada,
France, or Italia, the energy from soybean in daily dietary was zero, even in USA, the soy
energy is only 1. This indicates that soybean is the dominantly different diet factor between
the Eastern countries and the Western countries.
Interestingly the dramatically increased prostate cancer mortality in western countries, com‐
bined together with almost no soybean energy consumption, compare with very low mortal‐
ity in Asia (only 1/60 to 1/6 of that in West), combined with high soybean energy
consumption. This provided the important evidence for the consumption of soybean related
to the lower risk of prostate cancer mortality. Even another point of the higher animal ener‐
gy consumption in western diet, it is not that dominant as the difference of soy food.
Soy food Study site Finding Study type OR/RR P trend Reference
Soy food Japan protection cohort 0.52(0.29–0.90) 0.010 Kurahashi 2007
Miso soup 0.65(0.39–1.11) 0.220
Soymilk USA protection cohort 0.30(0.1 – 0.9 ) 0.020 Jacobsen 1998
Tofu Hawaii protection cohort 0.35(0.08–1.43) 0.054 Severson 1989
Soy food UK protection case-control 0.52(0.30–0.91) 0.340 Heald 2007
Tofu Japan protection case-control 0.47(0.20–1.08) 0.160
All soy products 0.53(0.24–1.14) 0.110 Sonoda 2004
Soyfoods China protection case-control 0.51(0.28–0.95) 0.061
Tofu 0.58(0.35–0.96) 0.032 Lee 2003
Soyfoods Hawaii,San
Francisco,
protection case-control 0.62(0.44–0.89) 0.060
All legumes Los
Angeles,
British
Columbia
and
Ontario
0.62(0.49–0.80) 0.0002 Kolonel 2000
Beans/lentils/
nuts
Canada protection case-control 0.69(0.53–0.91) 0.030 Jain 1999
Tofu, Soybean Canada protection case-control 0.80(0.60–1.10) 0.290 Villeneuve 1999
Soybean foods China protection case-control 0.29(0.11-0.79) 0.02 Li 2008
Baked beans UK protection case-control 0.57(0.34–0.95) N/A Key 1997
Garden peas UK 0.35(0.13–0.91) N/A
Table 2. N/A:no adequate dataEpidemiological studies on food intake of soy products and prostate caner risk(most
data summrized from Mol Nutr Food Res. 2009; 53: 217-226)
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Most epidemiological studies have suggested that the consumption of soy food is associated
with a reduction in prostate cancer risk in humans. Eight case-control studies and three cohort
studies have reported the protective effect of soy food, with odds ratios or relative risks ranging
from 0.3 to 0.80, including in China and Japan, where people consume more soybean food,
tofu, soymilk and natto. Here the epidemiological data are summarized in Table 2 [6].
Some cohort studies provided the convincing data on this issue. A population based pro‐
spective study recruited 43 509 Japanese men aged 45–74 years and followed them up for 10
years (1995 through 2004). For men aged 60 years, in whom soy food were associated with a
dose-dependent decrease in the risk of localized cancer, with RRs for men in the highest
quartile of soy food consumption compared with the lowest obtained a protective OR of 0.52
(95% confidence interval (CI) 0.29–0.90, P trend = 0.01) [7]. A cohort study in the USA with
225 incident cases of prostate cancer in 12395 California seventh-day adventist men showed
frequent consumption (more than once a day) of soymilk was associated with 70% reduction
of the risk of prostate cancer (RR = 0.3, 95%CI 0.1–0.9, P trend = 0.02) [8]. In an early cohort
study among 7999 men of Japanese ancestry who were first examined between 1965 and
1968 and then followed through to 1986, 174 incident cases of prostate cancer were recorded.
Increased consumption of tofu did not show statistical significant association with the risk
of prostate cancer (RR = 0.35, 95% CI 0.08–1.43) [9].
Much more case-control studies provided more evidence for the reduced risk of prostate
cancer associated with consumption of soy foods. First we concentrate some case-control
studies conducted in men living in China. Our group carried out a population-based case-
control study in China to investigate the possible correlation factors for prostate cancer, 28
cases from 3940 men over 50 years old with prostate-specific antigen screening in Chang‐
chun city in China, matched them with controls of low prostate-specific antigen value (< 4.1
ng/mL) by 1: 10 according to age and place of employment. In all ten food items, the con‐
sumption of soybeans was demonstrated the only factor to decrease the risk of prostate can‐
cer. Men who consumed the soybean product of Tofu and soymilk more than once per day
had a multivariate OR of 0.29 (95% CI, 0.11–0.79) compared with men who consumed soy‐
bean products less than once per week. The P for trend was 0.02. There was no significant
difference for any other dairy food (2). Another case-control study in China of 133 cases and
265 age- and residential community-matched controls from 12 cities were recruited. Results
showed that the age- and total calorie-adjusted OR of prostate cancer risk was 0.58 (95% CI
0.35-0.96, P= 0.032) in the highest tertile of Tofu intake comparing to the lowest tertile. There
were also statistically significant associations of intake of soy foods (OR 0.51; 95% CI 0.28–
0.95, P = 0.061) [10].
The case-control studies also provide the similar evidence for that the soy intake protect
against prostate cancer. A case-control study of diet and prostate cancer in Japan demon‐
strated the possible protective effect of traditional Japanese soybean die plays a preventive
role against prostate cancer in four geographical areas (Ibaraki, Fukuoka, Nara, and Hokkai‐
do) of Japan. All 140 cases and 140 age -matched hospital controls were analyzed to confirm
the consumption of fish and natto showed significantly decreasing linear trends for risk,
Soybean and Prostate Cancer
http://dx.doi.org/10.5772/ 52605
269
with RR of 0.53 (95% CI, 0.24-1.14) (P < 0.05) for all soybean products, 0.47 (95% CI,
0.20-1.08) for tofu, and 0.25 (95% CI, 0.05-1.24) for natto [11].
Not only has the case-control research conducted in Asian men supported the hypothesis
that the rich soybean products may protect against prostate cancer  but many case-control
studies conducted in western countries also provid the epidemiological evidence for the
protective effects of soy food against prostate cancer. A multiethnic case-control study car‐
ried out in Hawaii, San Francisco, and Los Angeles in the USA, and British Columbia and
Ontario in Canada, 1619 cases were diagnosed during 1987–1991 and were compared to
1618 controls of African-American, white, Japanese, and Chinese men. Controls were fre‐
quency- matched to cases on ethnicity, age, and region of residence of the case, in a ratio of
approximately 1:1. Intake of soy foods was inversely related to prostate cancer with OR of
0.62 (95% CI, 0.44–0.89). Results were similar when restricted to prostate-specific antigen
normal controls [12]. A further four case-control studies from USA, Canada and UK showed
similar results with a protective effect of consuming legumes (beans, lentils, garden peas,
etc.) against prostate cancer. A case-control study in Canada for a total study population
consisted of 617 incident cases of prostate cancer and 636 population controls from Ontario,
Quebec, and British Columbia. To obtain a decreasing, statistically significant association
was found with increasing intakes of beans/lentils/nuts (OR = 0.69, 95% CI, 0.53-0.91) [13].
Another population-based case-control study conducted in eight Canadian provinces. Risk
estimates were generated by applying multivariate logistic regression methods to 1623 his‐
tologically confirmed prostate cancer cases and 1623 male controls aged 50-74 to obtained a
OR 0.80 (95% CI, 0.60-1.10) of Tofu and Soybeans [14]. Not only soybean but also other le‐
gumes had the inverse relationship against prostate cancer. Oxford group in UK found the
baked beans had an OR of 0.57 (95% CI, 0.34-0.95); and garden peas had an OR of 0.35 (95%
CI, 0.13-0.91) [15]. And a population-based case-control study of diet, inherited susceptibili‐
ty and prostate cancer was undertaken in Scotland investigated a total of 433 cases of Scot‐
tish men and 483 controls aged 50-74 years, indicates the theoretical scope for reducing the
risk from prostate cancer, with the consumption of soy foods (adjusted OR 0.52, 95 % CI
0.30-0.91) [16].
All these data from both East and West, summarized in Table 2, provide the convincing epi‐
demiological evidence that the higher intake of soy products is associated with a reduced
risk of prostate cancer in human. Some experimental data in animal model also demonstrat‐
ed the possible protective effects for Soybean food against prostate cancer. For example,
Zhou group demonstrated that dietary soy products inhibit the experimental prostate tumor
growth through a combination of direct effects on tumor cells and indirect effects on tumor
neovasculature in mice, confirming that soy foods could act as a preventive factor against
prostate cancer in animal models [17].
Prostate cancer has marked geographic variations between countries. The data from both
western and eastern countries support the critical roles of soybean food in the protection of
prostate cancer.
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Part II: Correlation between prostate cancer and soybean isoflavones
from diet, serum epidemiological and laboratorial data
In recent decades, much evidence from epidemiological studies support the notion that fre‐
quent consumption of soybean foods, the most different diet between East and West, is ben‐
eficial for the protection against prostate cancer.
Soybeans are high in protein, for about 35% to 40% of the dry weight. They also contain 18%
polyunsaturated fats, 30% carbohydrates, and some vitamins, minerals. They are the only le‐
gume that provides ample amounts of the essential omega-3 fatty acid alpha-linolenic acid.2
Soybeans are a rich source of isoflavones (or phytoestrogens), a subclass of flavonoids that
bind to estrogen receptors (though not as strongly as estrogen). Isoflavones are also discov‐
ered in peanut, alfalfa; however, soybean contains the largest amounts of isoflavones in the
nature. Soybeans and soy foods such as tofu, soymilk, and miso are the only significant diet‐
ary sources of these phytoestrogens. In soybeans, isoflavones bound to a sugar molecule as
glycoside, and when soybean is fermented or digested, isoflavones could be released from
the bounded sugar [18].
Table 3 summarized the relationship between isoflavones levels and soy protein content in a
variety of soy-containing foods. The isoflavones in soymilk are lowest, 2.5mg per 100g soy‐
milk, may because in the fluid soymilk, the nutrition of soybeans is dissolved in water and
lower concentration of nutrition in soymilk, whereas isoflavones in soy flour are highest,
131.2 to 198.9mg per 100g. In tofu, a traditional soy food in Asia, the isoflavones are 27.9mg/
100g. In the traditional and very important Japanese soy food, the isoflavones in miso are
42.6mg/100g. The isoflavones in natto are 20mg/100g. The information from Table 3 clearly
provides the amounted isoflavones in some other soybean foods as well. In the most fre‐
quently diet, each gram of soy protein is associated with approximately 3.6 mg of isofla‐
vones in Tofu, 3.7 mg of isoflavones in whole bean based soymilk [19].
As the special nutrition in soybean compared to other plants, the isoflavones have many
health benefits, including protection against chronic diseases, menopausal symptoms, osteo‐
porosis and breast cancer or prostate cancer [20]. The most effective soy isoflavones are well
known as genistein and daidzein. Here, the relationship between each soybean isoflavones
and prostate cancer would be further illustrated.
The epidemiological evidence for the association of soy isoflavones and the prostate cancer
risk is still limited. Some epidemiological data, summarized in Table 4, evaluated the effects
of soybean isoflavones on prostate cancer. To date, one study suggests a causal relationship
between isoflavones and prostate cancer, but two cohorts and two case-control studies sug‐
gest that soy isoflavones, genistein and daidzein, have prophylactic effects on prostate can‐
cer. In addition,, an accumulating body of evidence from laboratory studies in recent
decades has suggested that diets rich in high concentration of isoflavones are associated
with anti-tumor effects in prostate cancer.
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estimated protein
(g/100 g)
total isoflavones
(mg/100 g)
isoflavone
(mg/g protein)
soy products
soybean chips 54.2 35 0.6
soy links frozen raw 3.9 15 3.9
natto boiled fermented 46.4 20 0.4
tofu, silken, firm 7.8 27.9 3.6
tempeh 14.9 43.5 2.9
miso 12.5 42.6 3.4
soy cheese, Cheddar 7.2 28 3.9
soy cheese, mozarella 7.7 32 4.2
soy cheese, Parmesan 6.4 36 5.6
soy milks
soy milk, isolate based, low isoflavone 3.3 2.5 0.7
soy milk, isolate based, high isoflavone 3.3 4.4 1.3
soy milk, whole bean based, low isoflavone 3.1 2.4 0.8
soy milk, whole bean based, high isoflavone 3.1 11.6 3.7
soy milk, entire bean 3.1 3.6 1.2
soy milk 3.5 9.7 2.8
soy protein materials
soy protein isolate, aqueous extract, type 1 85 114 1.3
soy protein isolate, aqueous extract, type 2 85 78.7 0.9
soy protein isolate, aqueous extract, type 3 85 103.4 1.2
soy protein isolate, alcohol extract 85 81.9 1.0
soy protein concentrate, alcohol extract 65 12.5 0.2
soy flour, defatted 50 131.2 2.6
soy flour, full fat, raw 35 177.9 5.1
soy flour, full fat, roasted 39 198.9 5.1
Table 3. Relationship between isoflavone levels and soy protein content in a variety of soy-containing foods  from J.
Agric. Food Chem. 2003; 51: 4146-4155 
2.1. Genistein
Genistein, firstly isolated from Genista tinctoria in 1899, was abundant in soybean. Even
though a serum case-control study suggested the promotion roles of genistein for the pros‐
tate cancer risk; most studies demonstrated its protective effects against prostate cancer.
Two cohort studies and two case control studies demonstrated the significant protective
roles of genistein against prostate cancer, with multivariate RRs (ORs) of 0.71, 0.52, 0.58 or
0.53, summarized in Table 4.
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Phynoestrog
en
Study site Findings Study type OR/RR Ptrend Reference
genistein
Europe protection cohort 0.71(0.53-0.96) 0.030
Japan protection cohort 0.52(0.30-0.90) 0.030
protection case-control 0.58(0.34-0.97) 0.040 Nagata 2007
protection case-control 0.53(0.29-0.97) 0.058 Lee 2003
Japan promotion serum case-
control
Akaza 2002
daidzein
Japan protection cohort 0.50(0.28-0.88) 0.040 Kurahashi
2007
Japan protection case-control 0.55(0.32-0.93) 0.020 Nagata 2007
China protection case-control 0.56(0.31-1.04) 0.116 Lee 2003
Japan protection serum case-
control
Akaza 2002
Table 4. Effects of photoestrogens on cacinogenesis of prostate cancer in epidemiological or animals experimental
data.
The population based prospective study recruited 43 509 Japanese men aged 45–74 years
and followed them up for 10 years (1995 through 2004). All 147 food items in 220 cases with
organ localized cancers was investigated the relationship of isoflavones intake and the risk
of prostate cancer. The increased consumption of genistein was found associated with the
decreased risk of localized prostate cancer. These results were strengthened when analysis
was restricted to men aged more than 60 years, in whom isoflavones and soy food were as‐
sociated with a dose-dependent decrease in the risk of localized cancer, with RRs for men in
the highest quartile of genistein consumption compared with the lowest of 0.52 (95% CI
0.30–0.90, P trend = 0.03) [7].
Another Japanese group examined associations between nutritional and the prevalence of
prostate cancer in a case-control study of Japanese men. Two hundred patients and 200 age-
matched controls were selected from 3 geographic areas of Japan. Isoflavones and their agly‐
cones (genistein and daidzein) were significantly associated with decreased risk, with the
OR for genistein 0.58 (95% CI 0.34–0.97, P trend = 0.04), indicating that isoflavones might be
an effective dietary protective factor against prostate cancer in Japanese men [21].
A case-control study in China showed an overall reduced risk of prostate cancer associated
with consumption of soy foods and genistein. In this study, 133 cases and 265 age- and resi‐
dential community-matched controls from 12 cities were recruited. Results showed that the
age- and total calorie-adjusted OR of prostate cancer risk was 0.58 (95% CI 0.35–0.96, P trend
= 0.032) comparing the highest tertile of tofu intake to the lowest tertile. There were also stat‐
istically significant associations of intake genistein (OR, 0.53; 95% CI, 0.29–0.97, P trend =
0.058) [10].
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Notably, a recent prospective investigation of plasma phytoestrogens and prostate cancer in
the European also found that higher plasma concentrations of genistein were associated
with lower risk of prostate cancer. They examined plasma concentrations of phyto-oestro‐
gens in relation to risk for subsequent prostate cancer in a case-control study nested in the
European Prospective Investigation into Cancer and Nutrition. Concentrations of isofla‐
vones genistein, daidzein and equol, and that of lignans enterolactone and enterodiol, were
measured in plasma samples for 950 prostate cancer cases and 1042 matched control partici‐
pants. Relative risks (RRs) for prostate cancer in relation to plasma concentrations of these
phyto-oestrogens were estimated by conditional logistic regression. Higher plasma concen‐
trations of genistein were associated with lower risk of prostate cancer, the RR among men
in the highest vs. the lowest fifth was 0.71 (95%CI 0.53-0.96, P trend=0.03). After adjustment
for potential confounders, this RR was 0.74 (95% CI 0.54-1.00, P trend=0.05). No statistically
significant associations were observed for circulating concentrations of daidzein, equol, en‐
terolactone or enterodiol in relation to overall risk for prostate cancer [22].
Laboratory studies revealed that Genistein has multiple functions in the antitumor effects
against prostate cancer, with the concentration as the prominent associated factor. In 2002,
an Italy group declared that at low concentration, about 1~10μM, genistein would stimulate
androgen-dependent prostate cancer cell line LNCaP growth, but when genistein was at
high concentration, more than 100μM, it would result in cell apoptosis in prostate caner [23].
The conclusions above were supported by the research of another Gao’s group, published in
the journal of the Prostate in 2004 [24].
In vitro studies in several prostate cancer cell lines have revealed that genistein directly in‐
hibit the growth of prostate cancer cells or through inducing apoptosis, affecting the expres‐
sion of a large number of genes that are related to the control of cell survival and
physiologic behaviors [25,26]. As tyrosine kinase inhibitor and topoisomerase inhibitor, gen‐
istein induces cancer cell apoptosis by upregulating the expression of cyclin-dependent kin‐
ase inhibitor p21 or inhibiting the activity of nuclear factor kappa B (NF-kB) signaling
pathways [27, 28]. Genistein is a potent inhibitor of protein–tyrosine kinase, which may at‐
tenuate the growth of cancer cells and decrease the level of oxidative DNA damage [29-31].
Genistein also reported to enhance the ability of endoglin, a component of the transforming
growth factor beta receptor complex, in suppression of the motility of prostate cancer cell
[32]. Moreover, genistein is also a potent inhibitor of angiogenesis and metastasis. It can ef‐
fectively inhibit cell invasion by inhibiting transforming growth factor β-mediated phos‐
phorylation of the p38 mitogen-activated protein kinase-activated protein kinase 2 and the
27 kDa heat shock protein [33].
The anti-tumor effects of genistein are demonstrated in the animal models. Animal experi‐
ments have also shown that dietary concentrations of genistein can inhibit metastasis of
prostate cancer [34]. Lifetime consumption of isolate/isoflavones has prevented spontaneous
development of metastasizing adenocarcinoma in Lobund–Wistar rat [35, 36]. Dietary genis‐
tein can also suppress the development of advanced prostate cancer in castrated transgenic
adenocarcinoma of mouse prostate (TRAMP) mice [37]. Some other result also indicated bi‐
phasic role for genistein in the regulation of prostate cancer growth and metastasis. A low
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concentration of 500 nmol/L of genistein to 12-week-old TRAMP-FVB mice as evidenced by
increased proliferation, invasion. But a pharmacologic dose (50 nmol/L) decreased prolifera‐
tion, invasion, and MMP-9 activity (>2.0-fold) concomitant with osteopotin reduction [38].
With 250 mg genistein/kg diet in treatments (TRAMP) mice model, the most significant ef‐
fect was seen in the TRAMP mice exposed to genistein throughout life (1-28 weeks) with a
50% decrease in poorly-differentiated cancerous lesions. In a separate experiment in castrat‐
ed TRAMP mice, dietary genistein suppressed the development of advanced prostate cancer
by 35% compared with controls. The data obtained in intact and castrated transgenic mice
suggest that genistein may be a promising chemopreventive agent against androgen-de‐
pendent and independent prostate cancers [39]. This group further identified the associated
signaling, and revealed that Genistein in the diet significantly inhibited the cell proliferation
by down-regulating tyrosine kinase regulated proteins, EGFR, IGF-1R, and down-regulating
the downstream mitogen-activated protein kinases, ERK-1 and ERK-2 in prostates in
TRAMP mice [37].
Genistein is demonstrated to be synergy with other phyto-chemicals together to inhibit the
growth of prostate cancer. For example, genistein and curcumin is reported could inhibit the
growth of prostate cancer cells in a synergistic way. Genistein, together with DIM, was
proved to repress the proliferation of androgen-dependent prostate cancer cell line LNCaP
and androgen-independent prostate cancer cell line PC-3 [40]. Genistein, together with bio‐
chanin A, could also inhibit the growth of human prostate cancer cells [41]. Genistein is also
reported acts as a radiosensitizer for prostate cancer both in vitro and in vivo inhibit meta‐
stasis of prostate cancer [34].
Based on the studies above, a conclusion is deduced that genistein showed protective effects
against prostate cancer, in vivo and in vitro, at its high concentration.
2.2. Daidzein
Daidzein is another important soy isoflavone. Most of epidemiological studies prove that
daidzein contributes to the reduction of prostate cancer risk and the prevention of prostate
cancer. A cohort study and two case control studies demonstrated its significant preventive
roles of daidzein for the prostate cancer prevention, with multivariate RRs (ORs) of 0.50,
0.55 or 0.56, summarized in Table 4.
Several studies indicated that daidzein might be an effective dietary protective factor against
prostate  cancer in Japanese men.  One cohort  study of  the population based prospective
study recruited 43 509 Japanese men aged 45–74 years mentioned above and followed them
up for 10 years. From 147 food items in 220 cases with organ localized cancers was inves‐
tigated and isoflavones intake was founded to be associated with the risk of prostate can‐
cer.  In  men aged more  than  60  years,  RRs  for  men in  the  highest  quartile  of  daidzein
consumption compared with the lowest of 0.50 (95%CI 0.28-0.88, P trend = 0.04) [7]. Anoth‐
er Japanese group examined associations between nutritional and the prevalence of pros‐
tate cancer in a case-control study in Japanese men. Two hundred patients and 200 age-
matched controls were selected from 3 geographic areas of Japan, demonstrated that daidzein
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were significantly associated with decreased risk,  with the OR 0.55 (95% CI 0.32–0.93,  P
trend = 0.02) for daidzein [21].
A case-control study in China showed an overall reduced risk of prostate cancer associated
with consumption of soy daidzein. In this study, 133 cases and 265 age- and residential com‐
munity-matched controls from 12 cities were recruited. Results showed that the age- and to‐
tal calorie-adjusted OR of prostate cancer risk was 0.58 (95% CI 0.35–0.96, P trend = 0.032)
comparing the highest tertile of tofu intake to the lowest tertile. There were even not statisti‐
cally significant associations, but the protective trend for the intake of daidzein (OR, 0.56;
95% CI, 0.31–1.04, P trend = 0.116) [10].
Daidzein displays the modest protective effect against prostate cancer from the experimen‐
tal data. Daidzein could act as a radiosensitizer against prostate cancer and an inhibitor of
cell growth. Daidzein inhibited cell growth and synergized with radiation, affecting APE1/
Ref-1, NF-kappaB and HIF-1alpha, but at lower levels than genistein or soy [42].
In addition, the protective effect on prostate cancer was strengthened after daidzein was
combined with genistein, compared to individual one. The study from Oregon State Univer‐
sity demonstrated daidzein and genistein could also induce cell apoptosis in benign prostate
hyperplasia (BPH) cells at concentration of 25 μM. Soy extractions were indicated more ef‐
fective as chemopreventive agents than genistein or daidzein. A combination of active soy-
derived compounds is demonstrated more efficacious and safer as chemopreventive agents
than individual compound. Soy extracts also increased Bax expression in PC3 cells [43]. Iso‐
flavones exert their chemopreventive properties by affecting apoptosis signaling TRAIL (tu‐
mor necrosis factor-related apoptosis-inducing ligand) pathways in prostate cancer LNCaP
cells. The chemopreventive effects of soy foods on prostate cancer are associated with isofla‐
vone-induced support of TRAIL-mediated apoptotic death [44].
Soy isoflavones, including daidzein and genistein, exert anticarcinogenic effects against
prostate cancer, proposed that soy extracts, containing a mixture of soy isoflavones and oth‐
er bioactive components, would be a more potent chemo-preventive agent than individual
soy isoflavones.
Part III: The mechanisms of prevention effects of soybean phyto-
estrogens against prostate cancer.
Isoflavones are the best-known phyto-estrogens, are a diverse group of naturally soy com‐
pounds, play important roles in prostate cancer inhibition. The consumptions of soy isofla‐
vone are investigated to be an effective protection factor against certain diseases. And the
products rich in isoflavones might protect against enlargement of the male prostate gland,
slow prostate cancer growth and lead to prostate cancer cell death.
The chemical structure-based ligand and receptor binding is the most important primary
step in generating downstream signal transduction. To reveal their mechanisms of preven‐
tion effects  against  prostate  cancer,  their  specific  structures  for  the receptor  binding are
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illustrated. Isoflavones are classified to phyto-estrogens, because their structures are simi‐
lar to estradiol (17β-oestradiol), also could mimic estrogenic effect to bind to estrogen recep‐
tors. However, their structures are similar not only to estradiol, but also to dihydrotestosterone
(DHT),  the  most  important  steroid  hormone  in  male.  DHT and 17β-oestradiol,  endoge‐
nous steroid hormones,  have a  four-ringed carbon backbone,  where as  non-steroid hor‐
mone  thyroxin  has  a  quite  different  structure  from them (Figure  2).  The  isoflavones  of
genistein and daidzein are two phyto-oestrogens found at very high levels in soy formu‐
la. Flavone, another group of phyto-estrogens, is found abundant in many plants. The struc‐
tures of genistein, daidzein and flavone showed similar properties: a hydrophobic core and
one or two terminal polar groups, similar to 17β-oestradiol or DHT (Figure 2),  have the
ability to cause estrogenic or/and anti-testosterone effects through the modulation of andro‐
gen receptor (AR) transactivation.
Figure 2. Molecular formulas of ligand compounds, two endogenous steroid hormones of dihydrotestosterone (DHT)
and 17β-oestradiol, one endogenous non-steroidal hormone, thyroxin, and three phyto-estrogens of genistein, daid‐
zein and flavone.  from Asian J Androl. 2010; 12: 535-547 
The normal development and maintenance of the prostate is dependent on androgen acting
through the AR, which is driven by DHT plays a critical role in prostate cancer development
and progression. AR expression is maintained throughout prostate cancer progression, and
the majority of androgen-independent or hormone refractory prostate cancers with the over-
expression or the mutation of AR. This progress may be affected by the soybean phyto-oestro‐
gens, as mimic oestrogens, compete the same binding sites of AR that binds to DHT, further
affect androgen-controlled AR mediated prostate cancer growth and development [45].
To reveal the mechanisms of these isoflavones for prostate cancer, our group adopted a
computerized approach to examine the interaction of the human AR and isoflavone (genis‐
tein or daidzein), whereas the interaction of AR and flavone was set up as a positive control.
Auto Dock method was adopted to summarize the roles of genistein, daidzein in AR activity
regulation, further to evaluate the importance of isoflavones for the tumor repression
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against prostate cancer. Auto Dock applies a half-flexible docking method, which permits
small molecular conformation changes. Based on a complex ‘lock-and-key model’, it is an
excellent method to reveal ligand–receptor binding. The result of computer stimulation from
Auto Dock contains two parts, one is the binding site of a ligand docked in the receptor and
the other is the binding affinity when a ligand is docked in the receptor.
The 3D spatial structure of AR-LBD was obtained from RCSB Protein Data Bank and its PDB
ID is 2ama (676-919AA). The positive-control docking result showed that 17β-oestradiol fit
the ligand-binding site of AR, at the same position in AR as its natural ligand, DHT. The
negative control, thyroxine, showed a quite different binding position with external docking
site (Figure 3A). Comparing the three endogenous ligands, thyroxine was expected to have
the weakest binding to AR and the highest affinity energy, which we measured at -5.4 kcal
mol-1. Very strong binding to AR with lower affinity energies was expected in the two ste‐
roid hormones, with affinity energies of -11.2 kcal mol-1 for DHT and -10.7 kcal mol-1 for 17β-
oestradiol (Figure 3B) [46].
Figure 3. Auto docking analysis of endogenous hormones or phyto-estrogens binding to androgen receptor.(A) Posi‐
tions of the steroid hormones of DHT or 17β-oestradiol, endogenous non-steroid hormone, thyroxin, phyto-estrogens
of genistein, daidzein or flavone binding to androgen receptor.(B): The affinity energies of each ligand binding to an‐
drogen receptor.  from Asian J Androl. 2010; 12: 535-547 
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Genistein and daidzein are abundant in soy formula and as healthy ingredient in soybean to
protect against prostate cancer. To understand the role of the isoflavone compounds in pros‐
tate cancer, a computerized auto-dock system was adopted to examine the interactions be‐
tween the human AR and phyto-oestrogens (genistein, daidzein, and flavone). As shown in
Figure 3 genistein, daidzein and flavone fit in the middle region of the AR-LBD (Figure 3A),
the same as DHT and 17β-estradiol. The affinities of them were expected to lie between the
affinities of thyroxin and 17β-estradiol. Genistein and daidzein, soy isoflavones, showed af‐
finity energies of -8.5 and -8.7 kcal mol-1, respectively, which were very similar to the affinity
energy of flavone of -8.8 kcal mol-1. From that result, we concluded that the three (iso) fla‐
vones exhibit similar binding affinities to AR (Figure 3B). Considering their sharing of a
binding site with estradiol, their affinities for AR and quantities potentially consumed in the
diet, these phyto-estrogens could have significant effects on AR and AR-related cancers [46].
The phyto-estrogens (genistein, daidzein and flavone) can bind to AR in an Auto Dock mod‐
el and can be regarded as androgenic effectors, suggesting important roles for them in AR-
mediated cancers. Interestingly, all these phyto-estrogens are reported to be associated with
prostate cancer, so we consider them AR-related phyto-estrogens. We summarized some re‐
cent data about the effects of them on AR-mediated transcriptional activity and on prostate
tumorigenesis in Table 5. Genistein, daidzein and flavone, implicated as androgenic effec‐
tors in our research, indeed regulate AR-mediated PSA transcriptional activity. They have
been demonstrated previously to either enhance AR-mediated transcriptional activity or in‐
hibit DHT induced AR-mediated PSA activity. Moreover, isoflavones or soy beverage has
already been shown in Phase II trials to decrease PSA levels in prostate cancer patients. It is
noteworthy that two recent phase II trials showed that isoflavones or soy beverage can de‐
crease PSA levels in prostate cancer patients, suggesting that androgen receptor target genes
can be regulated by isoflavones or flavones [46].
Phynoestrogen Findings Study type Reference
genistein inhibition of R1881-induced AR mediated pPSA-luc
activity
reporter assay Davis 2002
decrease AR binding to ARE EMSA
inhibition of R1881-induced AR mediated pPSA-luc
activity
reporter assay Gao 2004
enhancement of AR mediated pPSA/ARE/Probasin/
MMTV-luc
daidzein enhancement of AR (with ARA) mediated MMTV-luc reporter assay Chen 2007
flavone inhibition of DHT-induced AR mediated pPSA-luc activity reporter assay Rosenberg 2002
soy food decline of serum PSA PhaseII trail Kwan 2010
Pendleton 2008
Table 5. Effects of photoestrogens on AR mediated transcriptional activity from Asian J Androl. 2010; 12: 535-547 
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The mechanism of these phyto-estrogens against prostate cancer has been studied, some lab‐
oratory studies demonstrated that phyto-estrogens might not only mimic estrogenic activi‐
ties but also interfere with other steroid hormones, for example DHT, the natural androgen
in men. In human body, the activity of DHT binding with androgen receptor can be weaken
in the presence of a large amount of these phyto-estrogens, genistein, daidzein and flavone.
The findings in Auto Dock interestingly demonstrate that phyto-estrogens are displayed the
great binding abilities to AR, demonstrating their disrupt effects against DHT/AR binding as
anti-androgenic effectors, supporting the epidemiological studies that soybean were the po‐
tential inhibitor for prostate cancer cell growth related to AR. Figure 4 illustrated clearly the
mechanism of phyto-estrogens against prostate cancer. The different consumption of soy foods
and the different concentrations of isoflavones possibly disrupt the endogenous DHT bind‐
ing to AR in the prostate and thus inhibited DHT induced AR translocation and AR-mediat‐
ed PSA transactivation, thus reduce prostate cancer risk. As the antagonists of androgen, phyto-
estrogens are ale to inhibit the cell growth induced by androgen in prostate gland.
Figure 4. The mechanism of protective effect of genistein, daidzein or flavone against prostate cancer.
The reasons that Asian populations have lower rates of hormone-dependent cancers (breast,
prostate) and lower incidences of menopausal symptoms and osteoporosis than Westerners
are still need to be further revealed. However, the association of the large quantities of soy
products consumption in Asian populations with the reduction in the risk of prostate can‐
cer, provides a unique insight for the beneficial effects of soy foods. Soy food display com‐
pletely different consumption between eastern and western populations. The geometric
mean levels of plasma total isoflavonoids were demonstrated to be 7-10 times higher in Jap‐
anese men than in Finnish men. Asian immigrants living in Western nations also have in‐
creased risk of these maladies as they ‘Westernize’ their diets to include more protein and
fat and reduce their soy intake. This provides a good explanation for much epidemiological
data, indicating the significant protective effect of (iso) flavones for prostate cancer.
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The much higher serum phyto-estrogen levels could hypothetically inhibit the growth of
prostate cancer in Chinese and Japanese men, which may give a good explanation for the
quite low incidence and mortality from prostate cancer in Japan or China. The novel impor‐
tant insights for soy food against prostate cancer need to be further illustrated. Soy-based
food products are expected to introduce more to the western markets and to have more con‐
sumption in western daily diet.
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